review
remark
author
read
great
interest
manuscript
entitl
novel
peptid
inactiv
zika
viru
potenti
treatment
infect
pregnant
women
yu
et
al
studi
provid
promis
discoveri
peptid
design
deriv
stem
region
zikv
e
protein
potent
inhibit
vitro
vivo
infect
zikv
author
demonstr
interact
zikv
surfac
protein
disrupt
integr
viral
membran
result
releas
viral
genom
rna
inactiv
zikv
particl
intraperiton
administr
highli
effect
protect
type
interferon
receptordefici
mice
lethal
zikv
challeng
importantli
author
shown
could
penetrat
e
placent
barrier
enter
fetu
tissu
safe
use
pregnant
mice
fetus
therefor
peptid
great
potenti
develop
safe
effect
antizikv
drug
treat
zikv
infect
highrisk
popul
particularli
pregnant
women
overal
experi
studi
perform
rigor
result
great
import
paper
clearli
written
attract
interest
research
work
relat
area
stimul
progress
develop
antizikv
therapeut
howev
recommend
need
consid
order
strengthen
manuscript
make
result
claim
paper
convinc
scientif
commun
divid
major
minor
point
major
point
recent
two
paper
publish
show
zikv
could
infect
mous
testi
caus
damag
lead
male
infertil
natur
author
manuscript
demonstr
peptid
detect
mous
organ
liver
kidney
spleen
heart
well
placenta
fetal
tissu
would
interest
author
abl
detect
presenc
peptid
mous
testi
tissu
also
enter
testi
applic
peptid
may
prevent
testi
damag
caus
zikv
infect
author
demonstr
peptid
interact
zikv
e
protein
express
uninfect
cell
howev
unclear
whether
interact
zikv
surfac
protein
em
dimer
would
suggest
author
show
whether
peptid
interact
zikv
surfac
protein
express
zikvinfect
cell
minor
point
figur
amino
acid
residu
peptid
number
pleas
updat
discuss
antizikv
antibodi
line
cite
latest
public
sapparapu
g
et
al
neutral
human
antibodi
prevent
zika
viru
replic
fetal
diseas
mice
natur
http
dx
fig
reason
standard
plaqu
assay
use
fig
control
peptid
control
imag
critiqu
scrambl
peptid
deriv
would
best
control
use
throughout
flow
plot
look
differ
gate
drawn
includ
half
appear
neg
popul
minor
shift
popul
probabl
cell
fluorsec
around
x
axi
posit
one
next
neg
popul
given
lot
background
also
author
demonstr
cell
zikv
eposit
one
bind
fairli
easi
given
alreadi
label
fig
author
present
new
peptid
drug
amino
acid
efficaci
zika
viru
zikv
place
particular
threat
pregnant
women
specif
develop
fetu
via
teratogen
effect
synthet
peptid
deriv
stem
region
zikv
envelop
protein
abl
penetr
placent
barrier
pregnant
noninfect
mice
convers
daili
inject
protect
nonpregn
mice
lethal
infect
challeng
zikv
peptid
drug
previous
use
pregnant
women
prevent
hiv
transmiss
child
base
present
data
concept
seem
promis
mode
action
manuscript
show
disrupt
membran
envelop
zikv
lead
releas
viral
genom
thu
abrog
infect
use
method
well
suit
address
rais
research
question
experi
well
control
includ
unrel
peptid
virus
nevertheless
sever
key
point
rout
viru
challeng
safeti
profil
need
address
outlin
manuscript
may
suit
public
natur
commun
major
comment
result
reach
fetus
noninfect
mice
ivi
imag
fluoresc
label
fig
seem
disconnect
data
show
protect
adult
pregnant
mice
zikv
infect
surviv
data
fig
major
claim
manuscript
use
pregnanc
protect
fet
use
zikv
infect
claim
actual
address
data
author
need
provid
evid
prevent
teratogen
effect
pregnant
mice
protect
develop
fetus
zikv
infect
experi
c
ould
perform
use
lower
subleth
dose
zikv
pregnant
mice
determin
fetal
develop
fig
author
claim
safe
peptid
drug
candid
use
pregnant
women
safeti
howev
test
pregnant
mice
dose
protect
nonpregn
mice
zikv
infect
mgkg
higher
dose
mgkg
even
though
show
vitro
cytotox
cell
line
fig
mous
red
blood
cell
fig
perform
test
mice
suffici
conclud
toxic
vivo
along
line
shift
fluoresc
eprotein
neg
cell
fig
may
indic
nonspecif
bind
noninfect
cell
reach
noninfect
fetus
fig
suggest
bind
noninfect
cell
potenti
offtarget
effect
consequ
doseescal
studi
pregnant
mice
need
perform
determin
potenti
toxic
test
efficaci
vivo
mice
inject
intraperiton
one
hour
infect
zikv
rout
addit
vitro
experi
perform
via
preincub
zikv
hour
procedur
reflect
natur
event
occur
zikv
transmiss
via
infect
mosquito
manuscript
would
larg
benefit
show
viru
inocul
treatment
independ
author
could
instanc
inocul
zikv
intraven
subcutan
intraderm
model
natur
rout
viru
transmiss
inject
intraperiton
along
line
point
test
spread
fetu
perform
via
intraven
inject
line
test
efficaci
drug
zikv
infect
perform
via
ip
inject
test
spread
fetu
rout
inocul
perform
test
efficaci
drug
line
author
mention
america
addit
africa
asia
pacif
region
area
risk
zikv
transmiss
review
remark
author
overal
experi
studi
perform
rigor
result
great
import
paper
clearli
written
attract
interest
research
work
relat
area
stimul
progress
develop
antizikv
therapeut
howev
recommend
need
consid
order
strengthen
manuscript
make
result
claim
paper
convinc
scientif
commun
divid
major
minor
point
thank
review
encourag
comment
help
suggest
actual
zikv
infect
pregnant
woman
caus
sever
congenit
brain
development
abnorm
fetu
well
infect
testi
caus
damag
lead
male
infertil
therefor
also
detect
distribut
genit
organ
male
mice
supplementari
figur
show
could
distribut
genit
organ
male
mice
suggest
may
prevent
testi
damag
caus
zikv
howev
experi
need
carri
confirm
find
respons
thank
review
help
suggest
determin
interact
zikv
surfac
protein
express
zikvinfect
cell
shown
supplementari
figur
e
protein
green
stain
anti
mab
red
overlap
coloc
togeth
supplementari
figur
flow
cytometri
assay
supplementari
figur
bound
zikvinfect
significantli
higher
mockinfect
cell
result
suggest
peptid
interact
zikv
surfac
protein
express
zikvinfect
cell
immunofluoresc
stain
assay
green
zikv
e
protein
red
blue
nuclei
scale
bar
b
flow
cytometri
assay
incub
zikvor
mockinfect
cell
cell
wash
five
time
process
bd
accuri
flow
cytomet
result
ad
revis
manuscript
line
similar
result
obtain
zikvinfect
supplementari
figur
relat
method
ad
revis
manuscript
line
test
bind
zikvinfect
cell
cell
seed
cover
slip
zikv
mock
infect
fix
pfa
perfor
triton
block
bsa
cell
incub
anti
mab
wash
cell
incub
alexa
fluor
donkey
antimous
antibodi
rt
h
anoth
wash
cover
slip
seal
scan
leica
confoc
microscop
figur
amino
acid
residu
peptid
number
respons
peptid
deriv
membraneproxim
stem
region
residu
zikv
e
protein
therefor
number
peptid
figur
human
monoclon
antibodi
could
broadli
neutral
infect
diverg
zikv
strain
howev
high
cost
may
limit
applic
develop
countri
brazil
line
revis
manuscript
modif
antizikv
antibodi
decreas
bind
may
reduc
risk
ade
howev
may
increas
cost
antibodi
line
revis
manuscript
respons
abbrevi
e
protein
explain
upon
first
appear
manuscript
english
grammar
need
brush
placenta
barrier
line
fever
rash
line
etc
respons
thank
done
best
correct
english
grammar
error
manuscript
figur
appear
figur
adjust
figur
appear
sequenc
order
panel
figur
adjust
accordingli
line
subtitl
method
section
assay
antivir
activ
cytotox
chang
assay
antivir
activ
cytotox
experi
includ
section
chang
subtitl
accord
review
suggest
line
refer
relat
pseudotyp
merscov
refer
provid
prepar
pseudotyp
vsv
apolog
mistak
ad
follow
paragraph
pseudotyp
vsv
merscov
set
unrel
viru
control
prepar
previous
describ
briefli
cell
cotransfect
plasmid
encod
merscov
protein
vsvg
protein
use
vigofect
supernat
contain
pseudotyp
merscov
vsv
harvest
h
posttransfect
cell
infect
pseudotyp
virus
describ
line
revis
manuscript
author
describ
develop
character
peptid
deriv
zikv
e
protein
use
fusion
inhibitor
zikv
use
pregnant
women
manuscript
detail
inhibitori
properti
zikv
vitro
distribut
vivo
abil
interrupt
pathogenesi
mous
model
paper
offer
sever
novelti
includ
peptid
could
potenti
move
forward
use
human
manuscript
fall
short
especi
given
titl
suggest
may
benefici
use
pregnant
women
paper
even
demonstr
mice
thu
stretch
mislead
write
titl
major
find
respons
thank
review
insight
comment
help
us
improv
manuscript
chang
titl
novel
antivir
peptid
inactiv
zika
viru
prevent
infect
pregnant
mice
fetus
respond
review
critiqu
one
one
shown
respons
tri
time
studi
accord
construct
suggest
administ
peptid
mice
h
inocul
zikv
found
treat
mice
survi
supplementari
figur
viral
load
mice
day
postinfect
lower
vehicletr
mice
p
supplementari
figur
result
indic
peptid
still
protect
activ
vivo
even
administ
h
zikv
infect
ad
result
revis
manuscript
twentyfour
hour
inocul
zikv
treatment
still
could
protect
mice
death
p
supplementari
figur
viral
load
mice
day
postinfect
lower
vehicletr
mice
p
supplementari
figur
although
inactiv
zikv
earli
stage
viral
replic
consecut
inject
zikv
penetr
cell
could
still
provid
protect
infect
mice
possibl
inactiv
newli
produc
zikv
virion
prevent
infect
target
cell
line
revis
manuscript
studi
could
obtain
mice
anim
supplier
china
therefor
test
time
point
administr
peptid
futur
obtain
enough
mice
experi
respons
ye
peptid
could
block
transmiss
zikv
transplacent
mice
ad
experi
prove
new
figur
relat
result
revis
manuscript
line
determin
whether
could
protect
vertic
transmiss
zikv
pregnant
mice
infect
zikv
describ
previous
treat
mgkg
bodi
weight
vehicl
control
result
show
treatment
could
reduc
viremia
zikvinfect
pregnant
mice
p
figur
time
viral
rna
load
placenta
pregnant
mice
significantli
lower
vehicletr
mice
p
infect
rate
decreas
figur
interestingli
treatment
result
decreas
infect
rate
fetal
head
p
figur
result
suggest
may
inactiv
zikv
virion
either
virion
penetr
placenta
fetu
thu
reduc
infect
rate
fetus
well
protect
vertic
transmiss
zikv
pregnant
mice
antivir
efficaci
pregnant
mice
antivir
efficaci
pregnant
mice
evalu
use
method
previous
report
briefli
pregnant
mice
assign
randomli
two
group
infect
intraperiton
ip
x
pfu
zikv
one
h
later
infect
mice
ip
administ
mgkg
bodi
weight
vehicl
control
day
postinfect
mice
retroorbit
bled
measur
viremia
rtqpcr
two
embryo
pregnant
mous
randomli
collect
viral
rna
load
placenta
fetal
head
collect
embryo
determin
rtqpcr
fig
reason
standard
plaqu
assay
use
fig
control
peptid
control
imag
critiqu
scrambl
peptid
deriv
would
best
control
use
throughout
respons
base
previou
experi
other
public
quickli
develop
colorimetr
viral
infect
assay
use
kit
screen
antizikv
compound
sinc
found
method
conveni
quantit
reproduc
use
evalu
antizikv
activ
peptid
valid
colorimetr
assay
recent
confirm
muller
et
al
address
concern
perform
standard
plaqu
assay
determin
antizikv
activ
use
cell
shown
supplementari
figur
result
deriv
plaqu
assay
ic
consist
obtain
assay
ic
plaqu
reduct
assay
zikv
incub
differ
concentr
h
mixtur
ad
cell
seed
plate
h
viral
inoculum
remov
ml
dmem
fb
low
meltingpoint
agaros
overlaid
cell
four
five
day
later
cell
fix
pfa
stain
crystal
violet
overnight
b
plaqu
reduct
curv
plaqu
count
percentag
plaqu
reduct
calcul
ad
result
revis
manuscript
line
also
use
plaqu
reduct
assay
bhk
cell
test
antizikv
activ
shown
supplementari
figur
ic
suggest
result
deriv
plaqu
reduct
assay
consist
obtain
colorimetr
assay
respons
control
imag
control
peptid
ad
new
figur
shown
respons
agre
design
scrambl
peptid
ldiiaglsagfqggatfvdahgmvkasflggnw
use
pep
control
scrambl
pep
program
synthes
peptid
use
scrambl
peptid
control
repeat
seri
experi
compar
antizikv
activ
peptid
new
result
ad
follow
figur
figur
probabl
cell
fluorsec
around
x
axi
posit
one
next
neg
popul
given
lot
background
also
author
demonstr
cell
zikv
eposit
one
bind
fairli
easi
given
alreadi
label
fig
control
peptid
control
use
appear
neg
popul
minor
shift
popul
probabl
cell
fluorsec
around
x
axi
posit
one
next
neg
popul
given
lot
background
drawn
gate
cell
fluoresc
around
x
axi
inde
differ
reduc
shed
residu
may
contribut
background
respons
suggest
review
carri
immunofluoresc
stain
experi
use
zikvinfect
cell
high
express
level
e
protein
demonstr
zikv
eposit
cell
bind
although
wash
cell
longer
time
background
stain
remain
shown
supplementari
figur
green
e
protein
stain
red
fluoresc
overlap
suggest
could
bind
e
protein
zikvinfect
cell
immunofluoresc
stain
assay
green
zikv
e
protein
red
blue
nuclei
scale
bar
control
peptid
control
use
respons
scrambl
peptid
use
control
peptid
new
result
ad
new
figur
revis
manuscript
supplementari
figur
pharmacokinet
studi
sd
rat
g
administr
mgkg
intraven
via
tail
vein
blood
sampl
collect
retroorbit
bleed
h
administr
centrifug
rpm
min
obtain
serum
sampl
methanol
contain
peptid
mtweewdkkieeytkkieelikk
intern
standard
ad
serum
precipit
protein
centrifug
rpm
min
supernat
subject
liquid
chromatographytandem
mass
spectrometri
lcmsm
analysi
use
ab
sciex
qtrap
instrument
sciex
boston
usa
concentr
data
dosenorm
plot
serum
drug
concentr
time
curv
pk
solut
noncompartment
pharmacokinet
data
analysi
util
analyz
pharmacokinet
paramet
respons
apolog
confus
revis
manuscript
remov
figur
ad
follow
statement
legend
use
figur
highlight
yellow
figur
legend
new
figur
convert
origin
figur
supplementari
figur
fig
mous
red
blood
cell
fig
perform
test
mice
suffici
conclud
toxic
vivo
along
line
shift
fluoresc
eprotein
neg
cell
fig
may
indic
nonspecif
bind
noninfect
cell
reach
noninfect
fetus
fig
suggest
bind
noninfect
cell
potenti
offtarget
effect
consequ
doseescal
studi
pregnant
mice
need
perform
determin
potenti
toxic
thank
review
suggest
ad
experi
determin
potenti
vivo
toxic
dose
mgkg
bodi
weight
pregnant
mice
shown
new
figur
mom
pup
group
grew
normal
treat
group
campar
pb
group
show
signific
differ
alt
creatinin
blood
histolog
section
organ
normal
without
except
result
suggest
dose
high
mgkg
safe
pregnant
mice
higher
provid
protect
zikv
infect
vivo
inde
nonspecif
bind
observ
howev
believ
limit
nonspecif
bind
significantli
affect
vivo
efficaci
ad
follow
statement
revis
manuscript
line
overal
safe
pregnant
icr
mice
fetus
even
dose
high
mgkg
bodi
weight
higher
provid
protect
zikv
infect
vivo
surviv
zikvinfect
mice
mice
week
old
infect
pfu
zikv
intraperiton
inject
ip
rout
h
mice
treat
mgkg
bodi
weight
vehicl
control
mous
surviv
observ
record
daili
day
postinfect
b
viral
rna
load
sera
zikvinfect
mice
day
postinfect
mice
retroorbit
bled
measur
viral
rna
load
sera
rtqpcr
c
surviv
zikvinfect
mice
mice
week
old
infect
pfu
zikv
via
subcutan
rout
footpad
h
mice
treat
mgkg
bodi
weight
vehicl
control
mous
surviv
observ
record
daili
day
postinfect
viral
rna
load
sera
zikvinfect
mice
day
postinfect
mice
retroorbit
bled
measur
viral
rna
load
sera
rtqpcr
whisker
percentil
p
p
ad
result
revis
manuscript
line
similarli
treatment
protect
mice
death
caus
subcutan
administr
zikv
significantli
prolong
mst
day
end
experi
p
figur
viral
load
mice
day
postinfect
lower
vehicletr
mice
p
figur
ad
method
revis
manuscript
line
twelv
mice
assign
randomli
two
group
infect
x
pfu
zikv
via
subcutan
rout
footpad
infect
mice
ip
administ
mgkg
bodi
weight
vehicl
control
everi
day
consecut
day
postinfect
observ
examin
mice
perform
describ
along
line
point
test
spread
fetu
perform
via
intraven
inject
line
test
efficaci
drug
zikv
infect
perform
via
ip
inject
test
spread
fetu
rout
inocul
perform
test
efficaci
drug
respons
thank
suggest
accordingli
assess
distribut
peptid
intraperiton
inject
shown
supplementari
figur
fluoresc
seen
uteru
fetu
suggest
could
penetr
placent
barrier
enter
fetu
ad
result
revis
manuscript
